28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Dyslipidemia, characterized by abnormal blood lipid levels, is a major public health concern due to its association with atherosclerotic cardiovascular disease (ASCVD) and other cardiometabolic disorders. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Metabolic syndrome is a cluster of risk factors, including abdominal obesity, insulin resistance, hypertension, dyslipidemia (intended as an increase in triglyceride levels and a reduction in HDL cholesterol levels), and elevated fasting glucose, that increase the risk of cardiovascular disease and type 2 diabetes. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Enhancing CRC screening, early detection, and public health interventions can significantly reduce CRC-related mortality. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The 2024 Lancet Commission Report on dementia prevention has identified 14 modifiable risk factors that account for approximately 45% of global dementia cases. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
What we eat is a cornerstone of cardiovascular disease (CVD) prevention, but health professionals may not have a clear understanding of the current evidence-based research to underpin eating habits and recommendations. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A total of 43 trials of 327,264 participants with 42,016 major adverse cardiovascular events where included. 5 key findings →
Participants: 1,000 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cardiovascular disease risk factors begin in childhood and track into adulthood, increasing the possibility of impaired cardiometabolic health. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
With one of the scores, higher adherence to the EAT-Lancet diet was associated with a reduced risk of AD and all-cause dementia. 5 key findings →
Participants: 25,898 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Vascular contributions to cognitive impairment and dementia (VCID) are common and may be the most preventable cause of clinically significant cognitive decline. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Globally, the age-standardized incidence rates (ASIR) remained relatively steady. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Examining the risk of clinically diagnosed dementia in older adults, our study found a 65% increased risk of Alzheimer's disease (AD) dementia in individuals with diabetes compared with those without. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Higher ARTS score was associated (all ps < 0.01) with incident MCI (hazard ratio [HR] = 1.29), dementia (HR = 1.33), and stroke (HR = 1.52) and with diastolic/systolic blood pressure, self-reported hypertension, claudication, congestive heart failure, smoking, and glomerular filtration rate in the combined sample. 5 key findings →
Participants: 707 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia prevalence exceeds 40% for individuals in advanced old age, but that figure is not informative about the lifetime risk of ever having dementia or the risk of having dementia for different durations. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The crude prevalence of dementia significantly increased from 1985 to 2012 (6.7% in 1985, 5.7% in 1992, 7.1% in 1998, 12.5% in 2005, and 17.9% in 2012, p for trend < 0.01), but then decreased significantly from 2012 to 2022 (15.8% in 2017 and 12.1% in 2022; p for trend < 0.01). 5 key findings →
Design: cross-sectional Participants: 803 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
During a mean follow-up of 2.49 years (median, 1.99; standard deviation, 2.07; interquartile range, 2.66), dementia was significantly associated with increased stroke risk (aHR, 3.19; 95% confidence interval, 2.84-3.57). 5 key findings →
Design: cohort study Participants: 2,820 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Among a cohort of 118 006 individuals, the incident rate (IR) of dementia was 0.56/1000 person-years over a median follow-up period of 1.54 years among SGLT-2i users compared with 2.67/1000 person-years in DPP-4i users, over a median follow-up period of 1.79 years. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 322 participants (48.8% women; mean age 71.4 ± 6.4 years), moderate-to-severe OSA (apnea–hypopnea index [AHI] ≥ 15) was identified in 48.49%, despite the absence of prior diagnoses. 5 key findings →
Design: cross-sectional Participants: 322 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Hypertension is known to be a risk factor for cardiovascular diseases, but its relationship with cognitive impairment and dementia is an emerging area of study. 3 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A total of 281 dementia patients (mean age 74.9 ± 9.2 y, 46.3% females) and 281 age-matched controls (mean age 74.3 ± 4.6 y, 55.9% females) were included. 4 key findings →
Design: case-control study Participants: 281 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Over a median follow-up period of 4.33 years, 637 participants (7.27%) developed dementia. 5 key findings →
Design: longitudinal study Participants: 8,758 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
During follow-up, cholinergic WMHV was associated with an annual decline of Mini-Mental State Examination (MMSE) (β coefficient, -0.239; P = 0.004), and incident dementia (HR = 3.54; 95%CI: 2.05-6.10). 5 key findings →
Design: cross-sectional Participants: 751 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This was a retrospective analysis using nationally representative UK general practice population between 1998 and 2018, from electronic health records (Clinical Practice Research Datalink, CPRD, GOLD). 5 key findings →
Participants: 1,219,732 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
MAFLD was associated with an increased risk of WMH over 4.1 years in middle‐aged adults. 5 key findings →
Participants: 2,155 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our results pertaining to menopause-related characteristics, such as age at menopause or menopause hormonal therapy, did not replicate the literature reporting an association with WMH volumes. 5 key findings →
Design: cross-sectional Participants: 9,560 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
= 0.143). LVI was significantly associated with incident ischemic stroke in the MI cohort (adjusted hazard ratio [HR] 1.82, 95% CI 1.08-3.09), but not in the CCA cohort. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
10 of the 3,281 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →